GSK and Fleming Initiative scientists unite to target AMR with advanced AI

GlaxoSmithKline (GSK) will invest £45 million in a major new partnership with the Fleming Initiative at Imperial College London to accelerate the fight against antimicrobial resistance (AMR) using advanced artificial intelligence. Beginning in early 2026, both partners will launch six AI-powered “Grand Challenges” that span the full AMR spectrum: discovering new antibiotics and antifungals, predicting immune responses to infection, optimising antimicrobial prescribing, and modelling how resistant pathogens emerge and spread across populations. By combining GSK’s drug-development expertise with the Fleming Initiative’s cutting-edge AI and global AMR research network, the collaboration aims to generate actionable insights, novel treatment candidates, and real-time surveillance tools — ultimately helping health systems stay ahead of drug-resistant infections and preventing AMR from becoming a leading global health crisis.